Malignant pleural mesothelioma: Overview of the North American and European experience

Thoracic Surgery Clinics

Volumn 14, Issue 4 SPEC. ISS., 2004, Pages 435-445

  Kukreja, Jasleen ^a   Jaklitsch, Michael T ^c   Wiener, Daniel C ^b   Sugarbaker, David J ^a,b,c   Burgers, Sjaak ^d   Baas, Paul ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; BLEOMYCIN; CISPLATIN; DOXORUBICIN; DOXYCYCLINE; FOLIC ACID ANTAGONIST; GEMCITABINE; MITOMYCIN; PEMETREXED; TALC; TETRACYCLINE;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; EUROPE; HUMAN; MALIGNANT MESOTHELIOMA; NORTH AMERICA; PRIORITY JOURNAL; REVIEW;

EID: 4744340347     PISSN: 15474127     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thorsurg.2004.06.009     Document Type: Review

References (91)

1. W. Cooke Fibrosis of the lungs due to the inhalation of asbestos dust BMJ 2 1924 147
2. K. Lynch, and W. Smith Pulmonary asbestosis III: carcinoma of the lung in asbestos-silicosis Am J Cancer 24 1935 56 64
3. K.W. Lynch, and W.A. Smith Pulmonary asbestosis: a report of bronchial carcinoma and epithelial metaplasia Am J Cancer 36 1939 567 573
4. A. Stout Localized pleural mesothelioma: investigation of its characteristics and histogenesis by the method of tissue culture Arch Pathol 34 1942 951 964
5. J.C. Wagner, C.A. Sleggs, and P. Marchand Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province Br J Ind Med 17 1960 260 271
6. I. Selikoff, E. Hammond, and J. Churg Asbestos exposure and neoplasia JAMA 188 1964 22 26
7. I. Selikoff Cancer risk of asbestos exposure H. Hiatt J. Winston Origins of human cancer 1977 Cold Spring Laboratories Cold Spring Harbor, NY 1765 1784
8. SEER. Surveillance, epidemiology, end results program of the National Cancer Institute. Available at: http://www.seer.cancer.gov. Accessed June 2004
9. A. McDonald, and J. McDonald Epidemiology of malignant mesothelioma 1987 Grune & Stratton Orlando
10. A.D. McDonald, B.W. Case, A. Churg, A. Dufresne, G.W. Gibbs, and P. Sebastien Mesothelioma in Quebec chrysotile miners and millers: epidemiology and aetiology Ann Occup Hyg 41 1997 707 719
11. B. Price Analysis of current trends in United States mesothelioma incidence Am J Epidemiol 145 1977 211 218
12. R. Connelly, and R. Spirtas Demographic patterns for mesothelioma in the United States J Natl Cancer Inst 78 1987 1053 1060
13. J. Testa, H. Pass, and M. Carbone Molecular biology of mesothelioma V. DeVita S. Hellman S. Rosenberg Principles and practice of oncology 2001 Lippincott, Williams & Wilkins Philadelphia 1937 1943
14. M. Carbone, R.A. Kratzke, and J.R. Testa The pathogenesis of mesothelioma Semin Oncol 29 2002 2 17
15. M. Berry Mesothelioma incidence and community asbestos exposure Environ Res 75 1997 34 40
16. S. Singhal, and L. Kaiser Malignant mesothelioma: options for management Surg Clin North Am 82 2002 797 831
17. J. Peterson, S. Greenberg, and P. Buffler Non-asbestos-related malignant mesothelioma Cancer 54 1984 951 960
18. M. Carbone, H.I. Pass, P. Rizzo, M. Marinetti, M. DiMuzio, and D.J. Mew Simian 40 virus-like DNA sequences in human pleural mesothelioma Oncogene 9 1994 1781 1790
19. S. Murthy, and J. Testa Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma J Cell Physiol 180 1999 150 157
20. J. Steele Prognostic factors in mesothelioma Semin Oncol 29 2002 36 40
21. D. Sugarbaker, and M. Liptay Therapeutic approaches in malignant mesothelioma J. Aisner R. Arriagada M. Green N. Martini M. Perry Comprehensive textbook of thoracic oncology 1996 Williams and Wilkins Baltimore 786 798
22. A.A. Renshaw, B.R. Dean, K.H. Antman, D.J. Sugarbaker, and E.S. Cibas The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma Chest 111 1997 106 109
23. V. Rusch, and R. Ginsberg New concepts in the staging of mesothelioma J. Deslauriers L. Lacquet Thoracic surgery: surgical management of pleural diseases: international trends in thoracic surgery 1990 CV Mosby St. Louis 336 343
24. C. Boutin, F. Rey, J. Gouvernet, J.R. Viallat, P. Astoul, and V. Ledoray Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: prognosis and staging Cancer 72 1993 394 404
25. W.T. McCaughey, T.V. Colby, H. Battifora, A. Churg, J.M. Corson, and S.D. Greenberg Diagnosis of diffuse malignant mesothelioma: experience of a US/Canadian mesothelioma panel Mod Pathol 4 1991 342 353
26. E.G. Butchart, T. Ashcroft, W.C. Barnsley, and M.P. Holden Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura: experience with 29 patients Thorax 31 1976 15 24
27. V.W. Rusch Group TIMI A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group Chest 108 1995 1122 1128
28. D.J. Sugarbaker, R.M. Flores, M.T. Jaklitsch, W.G. Richards, G.M. Strauss, and J.M. Corson Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients J Thorac Cardiovasc Surg 117 1999 54 63
29. E. Patz, K. Shaffer, D. Piwnica-Worms, M. Jochelson, M. Sarin, and D. Sugarbaker Malignant pleural mesothelioma: value of CT and MR imaging in predicting respectability AJR Am J Roentgenol 159 1992 961 966
30. V.H. Gerbaudo, D.J. Sugarbaker, S. Britz-Cunningham, M.F. Di Carli, C. Mauceri, and S.T. Treves Assessment of malignant pleural mesothelioma with (18)F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology J Nucl Med 43 2002 1144 1149
31. N. Vogelzang, J. Herndon, and G. Clamon Paclitaxel (Taxol) for malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B (CALGB 9234) [abstract] Program/Proceedings of the American Society of Clinical Oncology 13 1994 1382
32. L. Herscher, S. Hahn, and H. Pass A phase I study of paclitaxel as a radiation sensitizer for the treatment of non-small cell lung cancer and mesothelioma [abstract] Program/Proceedings of the American Society of Clinical Oncology 14 1995 A1530
33. K. Antman, H. Pass, and A. Recht Benign and malignant mesothelioma V. DeVita S. Hellman S. Rosenberg Cancer: principles and practice of oncology 1989 JB Lippincott Philadelphia 1399 1414
34. H. Lerner, D. Schoenfeld, A. Martin, G. Falkson, and E. Borden Malignant mesothelioma: the Eastern Cooperative Oncology Group (ECOG) experience Cancer 52 1983 1981 1985
35. B. Zidar, S. Green, H. Pierce, R. Roach, S. Balcerzak, and L. Militello A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study Invest New Drugs 6 1988 223 226
36. H. Kindler, F. Millard, and J.I. Herndon Gemcitabine for malignant mesothelioma: a phase II trial by the cancer and leukemia group B Lung Cancer 31 2001 311 317
37. S. Swanson, and D. Sugarbaker Surgery and pleural space: fibrothorax, thoracoscopy, and pleurectomy G. Baum J. Crapo B. Celli J. Karlinsky Textbook of pulmonary diseases 1998 Lippincott-Raven Philadelphia 1499 1503
38. A.P. Chahinian, K. Antman, M. Goutsou, J.M. Corson, Y. Suzuki, and C. Modeas Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the cancer and leukemia group B J Clin Oncol 11 1993 1559 1565
39. N.J. Vogelzang, J.J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel, and P. Ruffie Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 21 2003 2636 2644
40. R. Bueno, K. Appasani, H. Mercer, S. Lester, and D. Sugarbaker The alpha folate receptor is highly activated in malignant pleural mesothelioma J Thorac Cardiovasc Surg 121 2001 225 233
41. A. Canto, R. Guijarro, A. Arnau, J. Galbis, M. Martorell, and R. Garcia Aguado Videothoracoscopy in the diagnosis and treatment of malignant pleural mesothelioma with associated pleural effusion J Thorac Cardiovasc Surg 45 1997 16 19
42. V. Rusch Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma Semin Thorac Cardiovasc Surg 9 1997 367 372
43. D. Sugarbaker, M. Jaklitsch, R. Bueno, W. Richards, J. Lukanich, and S. Mentzer Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies J Thorac Cardiovasc Surg 128 2004 138 146
44. L. Zellos, and D. Sugarbaker Multimodality treatment of diffuse malignant pleural mesothelioma Semin Oncol 29 2002 41 50
45. V. Rusch Mesothelioma and less common pleural tumors F. Pearson J. Cooper J. Deslauriers Thoracic surgery 2001 Churchill-Livingstone Philadelphia 1241 1263
46. D. Sugarbaker, W. Richards, I. Zellos, J. Wright, and O. Tretyakov Feasibility of pleurectomy and intraoperative bicavitary hyperthermic cisplatin lavage for mesothelioma Proc Am Soc Clin Oncol 22 2003 2494
47. H.I. Pass, T. Delaney, and A. Tochner Intrapleural photodynamic therapy: results of a phase I trial Ann Surg Oncol 1 1994 28 37
48. M. Bard, and P. Ruffie Malignant mesothelioma. Medical oncology: standards, new trends, trials - the French experience Lung Cancer 45 Suppl1 2004 S129 S131
49. B. Castagneto, S. Zai, L. Mutti, A. Lazzaro, R. Ridolfi, and E. Piccolini Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: results of a phase II study on 31 consecutive patients Lung Cancer 31 2001 303 310
50. K. Antman Current concepts: malignant mesothelioma N Engl J Med 303 1980 200 202
51. D.J. Sugarbaker, E.C. Heher, T.H. Lee, G. Cooper, S. Mentzer, and J.M. Corson Extrapleural pneumonectomy, chemotherapy and radiotherapy in the treatment of diffuse malignant pleural mesothelioma J Thorac Cardiovasc Surg 102 1991 10 15
52. D. Sugarbaker, G. Strauss, T. Lynch, W. Richards, S. Mentzer, and T. Lee Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma J Clin Oncol 11 1993 1172 1178
53. D. Sugarbaker, J. Garcia, and W. Richards Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma: results in 120 consecutive patients Ann Surg 224 1996 288 294
54. E. Cibas, J. Corson, and G. Pinkus The distinction of adenocarcinoma from malignant mesothelioma in cell blocks of effusions: the role of routine mucin histochemistry and immunohistochemical assessment of carcinoembryonic antigen, keratin proteins, epithelial membrane antigen, and milk fat globule-derived antigen Hum Pathol 18 1987 67 74
55. G.J. Gordon, R.V. Jensen, L.L. Hsiao, S.R. Gullans, J.E. Blumenstock, and W.G. Richards Using gene expression ratios to predict outcome among patients with mesothelioma J Natl Cancer Inst 95 2003 598 605
56. H. Wedler Lung cancer in asbestosis patients Arch Klin Med 191 1935 288 302
57. K. Hemminki, and X. Li Mesothelioma is a killer of urban men in Sweden Int J Cancer 105 2003 144 146
58. M. Huuskonen, A. Tossavainen, A. Karjalainen, J. Rinne, and J. Rantanen Finnish Institute of Occupational Health Asbestos Program 1987†"1992 Am J Ind Med 28 1995 123 142
59. J. Peto, A. Decarli, C. La Vecchia, F. Levi, and E. Negri The European mesothelioma epidemic Br J Cancer 79 1999 666 672
60. C. La Vecchia, A. Decarli, J. Peto, F. Levi, F. Tomei, and E. Negri An age, period and cohort analysis of pleural cancer mortality in Europe Eur J Cancer Prev 9 2000 179 184
61. O. Segura, A. Burdorf, and C. Looman Update of predictions of mortality from pleural mesothelioma in the Netherlands Surg Clin North Am 60 2003 50 55
62. C. Bianchi, A. Brollo, L. Ramani, and T. Bianchi Malignant mesothelioma in Central and Eastern Europe Acta Med Croatica 54 2000 161 164
63. M. Albin, C. Magnani, S. Krstev, E. Rapiti, and I. Shefer Asbestos and cancer: an overview of current trends in Europe Environ Health Perspect 107 1999 289 298
64. V. Galani, Constantopoulos, C. Manda-Stachouli, M. Frangou-Lazaridis, A. Mavridis, and M. Vassillou Additional proteins in BAL fluid of Metsovites environmentally exposed to asbestos: more evidence of "protection" against neoplasia? Chest 121 2002 273 278
65. L. Paoletti, D. Batisti, C. Bruno, M. Di Paola, A. Gianfagna, and M. Mastrantonio Unusually high incidence of malignant pleural mesothelioma in a town of eastern Sicily: an epidemiological and environmental study Arch Environ Health 55 2000 392 398
66. S. Emri, A. Demir, M. Dogan, H. Akay, B. Bozkurt, and M. Carbone Lung diseases due to environmental exposures to erionite and asbestos in Turkey Toxicol Lett 127 2002 251 257
67. M. Metintas, G. Hillderdal, and S. Metintas Malignant mesothelioma due to environmental exposure to erionite: follow-up of a Turkish emigrant cohort Eur Respir J 13 1999 523 526
68. V. Gennaro, F. Montanaro, A. Lazzarotto, M. Bianchelli, M.V. Celesia, and P.A. Canessa Incidenza ed eziologia professionale un area ad alto rischio Mesothelioma registry of the Liguria region. Incidence and occupational etiology in a high risk area Epidemiol Prev 24 2000 213 218
69. A. Burdorf, J.J. Barendregt, P.H. Swuste, and D.J. Heederik Future increase of the incidence of mesothelioma due to occupational exposure to asbestos in the past Ned Tijdschr Geneeskd 141 1997 1093 1098
70. British Thoracic Society Standards of Care Committee Statement on malignant mesothelioma in the United Kingdom Thorax 56 2001 250 265
71. P. Ruffie, M. Lehmann, F. Galateau-Salle, J. Lagrange, and J. Pairon Standards, options, and recommendations for the management of patients with malignant mesothelioma of the pleura: Federation Nationale des Centres de Lutte Contre le Cancer Bull Cancer 85 1998 545 561
72. F. Berrino, R. Cupocaccia, J. Esteve, G. Gatta, T. Hakulinen, and A. Micheli Survival of cancer patients in Europe: the EUROCARE-2 study 1999 International Agency for Research on Cancer Lyon 273
73. C. Boutin, P. Dumortier, F. Rey, J.R. Viallat, and P. DeVuyst Black spots concentrate oncogenic asbestos fibers in the parietal pleura: thoracoscopic and mineralogic study Am J Respir Crit Care Med 153 1996 444 449
74. Anonymous Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution Scand J Work Environ Health 23 1997 311 316
75. J. Jones The formation and function of the Mesothelioma Panel of the Commission of the European Communities 1993 Office for Official Publications of the European Communities Brussels
76. D. Curran, T. Sahmoud, P. Therasse, J. van Meerbeeck, P. Postmus, and G. Giaccone Prognostic factors in patients with pleural mesothelioma: the European organization for research and treatment of cancer experience J Clin Oncol 16 1998 145 152
77. J. Edwards, K. Abrams, J. Leverment, T. Spyt, D. Waller, and K. O'Byrne Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems Thorax 55 2000 731 735
78. M. Bredin, J. Corner, M. Krishnasamy, H. Plant, C. Bailey, and R. A'Heran Multicentre randomised controlled trial of nursing intervention for breathlessness in patients with lung cancer BMJ 318 1999 901 904
79. L. de Graaf-Strukowska, J. van der Zee, W. van Putten, and S. Senan Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura: a single-institution experience with 189 patients Int J Radiat Oncol Biol Phys 43 1999 511 516
80. C. Boutin, F. Rey, and J.R. Viallat Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma: a randomized trial of local radiotherapy Chest 108 1995 754 758
81. N. Vogelzang, J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel, and P. Ruffie Phase III study of permetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 21 2003 2636 2644
82. P. Baas, A. Ardizzoni, F. Grossi, K. Nackaerts, G. Numico, and E. Van Marck The activity of raltitrexed (Tomudex) in malignant pleural mesothelioima: an EORTC phase II study (08992) Eur J Cancer Prev 39 2003 353 357
83. J. Van Meerbeeck, C. Manegold, R. Gaafar, R. van Klaveren, M. Vincent, and C. Legrand A randomized phase III study of cisplatin with or without raltitredex in patients with malignant pleural mesothelioma: an intergroup study of the EORTC Lung Cancer Group and NCIC [late breaking abstract] Proc Am Soc Clin Oncol 23 2004 18
84. P. Bass Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine Semin Surg Oncol 29 2002 62 69
85. K. Fizazi, W.J. John, and N.J. Vogelzang The emerging role of antifolates in the treatment of malignant pleural mesothelioma Semin Surg Oncol 29 2002 77 81
86. Manegold C., Hoffman H., Fischer R., Lahm H., O'Byrne K., Wallder D. Diagnosis and treatment of pleural mesothelioma: current strategies and future concepts. 2nd Heidelberg Thoracic Symposium, Heidelberg, 2002
87. T. Aziz, A. Jilaihawi, and D. Prakash The management of malignant pleural mesothelioma: single centre experience in 10 years Eur J Cardiothorac Surg 22 2002 298 305
88. A. Martin-Ucar, J. Edwards, A. Rengajaran, S. Muller, and D. Walter Palliative surgical debulking in malignant mesothelioma: predictors of survival and symptom-control: results of surgery Eur J Cardiothorac Surg 20 2001 1117 1121
89. O. Soysal, N. Karaoglanoglu, S. Demiracan, S. Topcu, I. Tastepe, and S. Kaya Pleurectomy/decortication for palliation in malignant pleural mesothelioma: results of surgery Eur J Cardiothorac Surg 11 1997 210 213
90. H. Schouwink, E. Rutgers, J. van der Sjip, H. Oppelaar, N. van Zandwijk, and R. van Veen Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: dose finding and toxicity results Chest 120 2001 1167 1174
91. E. de Bree, S. van Ruth, P. Baas, E.J. Rutgers, N. van Zandwijk, and A.J. Witkamp Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma Chest 121 2002 480 487